Holen Sie sich die Stockscreener-App
63.61
2.51%
-1.64
Handel nachbörslich:
63.56
-0.05
-0.08%
Schlusskurs vom Vortag:
$65.25
Offen:
$64.85
24-Stunden-Volumen:
232.20K
Relative Volume:
0.60
Marktkapitalisierung:
$1.36B
Einnahmen:
$486.82M
Nettoeinkommen (Verlust:
$18.78M
KGV:
77.57
EPS:
0.82
Netto-Cashflow:
$100.45M
1W Leistung:
-5.03%
1M Leistung:
+8.33%
6M Leistung:
+15.07%
1J Leistung:
+0.27%
1-Tages-Spanne:
$63.27
$66.23
1-Wochen-Bereich:
$63.27
$66.86
52-Wochen-Spanne:
$52.50
$77.00
Ani Pharmaceuticals Inc Stock (ANIP) Company Profile
Firmenname
Ani Pharmaceuticals Inc
Sektor
Telefon
(218) 634-3500
Adresse
210 MAIN STREET WEST, BAUDETTE, MN
Vergleichen Sie ANIP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANIP
Ani Pharmaceuticals Inc
|
63.61 | 1.36B | 486.82M | 18.78M | 100.45M | 0.82 |
|
RGC
Regencell Bioscience Holdings Ltd
|
14.60 | 303.95B | 0 | -5.87M | -767.30K | -0.45 |
|
ZTS
Zoetis Inc
|
159.19 | 74.39B | 9.29B | 2.52B | 2.28B | 5.57 |
|
HLN
Haleon Plc Adr
|
10.36 | 48.97B | 14.35B | 1.85B | 0 | 0.4023 |
|
TAK
Takeda Pharmaceutical Co Adr
|
15.37 | 47.39B | 30.08B | 710.16M | 4.45B | 0.2182 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
16.65 | 20.17B | 16.54B | -1.64B | 749.00M | -1.45 |
Ani Pharmaceuticals Inc Stock (ANIP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-14 | Eingeleitet | Jefferies | Buy |
| 2025-03-12 | Eingeleitet | JP Morgan | Overweight |
| 2024-12-11 | Eingeleitet | Leerink Partners | Outperform |
| 2024-10-11 | Eingeleitet | Piper Sandler | Overweight |
| 2024-03-15 | Eingeleitet | CapitalOne | Overweight |
| 2023-08-22 | Bestätigt | H.C. Wainwright | Buy |
| 2023-03-01 | Eingeleitet | Guggenheim | Buy |
| 2022-09-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-11-02 | Eingeleitet | Truist | Buy |
| 2020-05-07 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2019-09-12 | Eingeleitet | Guggenheim | Buy |
| 2019-05-10 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2017-10-16 | Bestätigt | Canaccord Genuity | Buy |
| 2017-07-31 | Eingeleitet | Canaccord Genuity | Buy |
| 2017-02-22 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2016-06-23 | Eingeleitet | Raymond James | Strong Buy |
| 2016-05-24 | Herabstufung | Standpoint Research | Buy → Hold |
| 2015-11-13 | Eingeleitet | Standpoint Research | Buy |
| 2015-09-28 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2015-08-05 | Bestätigt | Oppenheimer | Outperform |
| 2015-08-04 | Bestätigt | ROTH Capital | Neutral |
| 2015-07-31 | Bestätigt | Oppenheimer | Outperform |
| 2015-07-15 | Bestätigt | ROTH Capital | Neutral |
| 2015-06-23 | Bestätigt | Oppenheimer | Outperform |
| 2015-05-18 | Bestätigt | ROTH Capital | Neutral |
| 2015-05-06 | Bestätigt | Oppenheimer | Outperform |
| 2015-04-10 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2015-02-26 | Bestätigt | ROTH Capital | Buy |
| 2015-02-18 | Bestätigt | Oppenheimer | Outperform |
Alle ansehen
Ani Pharmaceuticals Inc Aktie (ANIP) Neueste Nachrichten
ANI Pharmaceuticals Inc (ANIP) Shares Up 2.7% on Jun 18 - GuruFocus
ANI Pharmaceuticals (ANIP) Reveals New Preclinical Findings on Cortrophin Gel | ANIP Stock News - GuruFocus
ANI Pharmaceuticals Announces Presentation of New Preclinical Data - The Manila Times
Breakthrough Arthritis Treatment Data: Cortrophin Gel Successfully Reduces Joint Inflammation in Preclinical Study - Stock Titan
GAMMA Investing LLC Purchases 94,464 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 13,948 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Defense World
ANI Pharmaceuticals (ANIP) Stock Price, News & Analysis - MarketBeat
ANI Pharmaceuticals at Jefferies Conference: Strategic Growth in Rare Diseases - Investing.com Canada
ANI Pharmaceuticals To Present At Jefferies Global Conference; Webcast At 2:35 PM ET - Nasdaq
ANI Pharmaceuticals Inc (ANIP) Shares Up 3.19% on Jun 2 - GuruFocus
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Shares Sold by Nuveen Asset Management LLC - Defense World
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Grows Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Defense World
BNP Paribas Financial Markets Reduces Stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Defense World
ANI Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference - GlobeNewswire
Bank of America Corp DE Raises Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Defense World
ANI Pharmaceuticals CEO Nikhil Lalwani to Share Strategic Updates at Jefferies Healthcare Conference - Stock Titan
Top 3 Health Care Stocks That Could Lead To Your Biggest Gains This Quarter - Benzinga
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Receives Average Rating of “Buy” from Analysts - Defense World
3 Reasons to Avoid ANIP and 1 Stock to Buy Instead - Yahoo Finance
ANI Pharmaceuticals Expands Stock Plans and Shares By Investing.com - Investing.com Nigeria
ANI Pharmaceuticals initiates Phase IV trial of gel for acute gout flares - MSN
ANI Pharmaceuticals Expands Stock Plans and Shares - Investing.com Australia
ANI Pharmaceuticals Approves Key Proposals at Annual Meeting - TipRanks
Have Insiders Sold ANI Pharmaceuticals Shares Recently? - simplywall.st
ANI Pharmaceuticals Launches Phase 4 Trial of Cortrophin Gel for Acute Gout Flares - marketscreener.com
ANI Pharmaceuticals (ANIP) Starts Phase 4 Trial for Acute Gout Treatment | ANIP Stock News - GuruFocus
ANI Pharmaceuticals Announces Initiation of Phase 4 Clinical Trial of Purified Cortrophin® Gel for the Treatment of Acute Gout Flares - The Manila Times
ANI Pharmaceuticals Announces Initiation of Phase 4 - GlobeNewswire
ANI Raises Generics Guidance As Exclusive Prucalopride Drives Growth - insights.citeline.com
ANI Pharmaceuticals at H.C. Wainwright: Rare Disease Growth Focus By Investing.com - Investing.com India
ANI Pharmaceuticals To Present At H.C. Wainwright BioConnect Conference; Webcast At 1:30 PM ET - Nasdaq
Ameriprise Financial Inc. Raises Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Defense World
The Manufacturers Life Insurance Company Sells 291 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Defense World
We Think Shareholders Will Probably Be Generous With ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) CEO Compensation - simplywall.st
Price T Rowe Associates Inc. MD Has $403,000 Stock Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Defense World
Analysts Offer Insights on Healthcare Companies: ANI Pharmaceuticals (ANIP), Voyager Therapeutics (VYGR) and Privia Health Group (PRVA) - The Globe and Mail
Stifel Financial Corp Acquires 1,425 Shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) - Defense World
ANI Pharmaceuticals (ANIP) Price Target Raised by Raymond James - GuruFocus
ANI Pharmaceuticals to Participate at the H.C. Wainwright 3rd Annual BioConnect Conference at NASDAQ - GlobeNewswire
ANI Pharmaceuticals (ANIP) Receives Buy Rating from Guggenheim | - GuruFocus
ANI Pharmaceuticals (ANIP) Receives Buy Rating from Guggenheim | ANIP Stock News - GuruFocus
ANI Pharmaceuticals raises 2025 revenue guidance to $768M-$793M with 25%-29% growth - MSN
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q1 2025 Earnings Call Transcript - Insider Monkey
Earnings call transcript: ANI Pharmaceuticals beats Q1 2025 forecasts, stock surges - Investing.com UK
ANI Pharmaceuticals Inc (ANIP) Q1 2025 Earnings Call Highlights: Record Revenue and Strategic ... By GuruFocus - Investing.com Canada
Decoding ANI Pharmaceuticals Inc (ANIP): A Strategic SWOT Insigh - GuruFocus
Decoding ANI Pharmaceuticals Inc (ANIP): A Strategic SWOT Insight - GuruFocus
ANI Pharmaceuticals Reports Record Q1 2025 Results - TipRanks
Earnings call transcript: ANI Pharmaceuticals beats Q1 2025 forecasts, stock surges By Investing.com - Investing.com South Africa
Finanzdaten der Ani Pharmaceuticals Inc-Aktie (ANIP)
Umsatz
Nettogewinn
Free Cashflow
ENV
Ani Pharmaceuticals Inc-Aktie (ANIP) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Gutwerg Ori | SVP, GENERICS |
May 15 '25 |
Sale |
60.07 |
881 |
52,922 |
89,897 |
| Mutz Christopher | HEAD OF RARE DISEASE |
May 14 '25 |
Sale |
60.45 |
4,000 |
241,800 |
107,317 |
| Cook Meredith | SR. VP, GENERAL COUNSEL & SEC. |
May 13 '25 |
Sale |
62.20 |
400 |
24,880 |
79,745 |
| Shanmugam Muthusamy | HEAD OF R&D, COO-NOVITIUM OPS |
May 09 '25 |
Sale |
76.83 |
700 |
53,781 |
631,920 |
1.09%
0.60%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):